机构负责人：纪立农

联系人：任倩

邮箱：qianren@pku.edu.cn

电话：010-88324100

地址：北京市西城区西直门南大街11号

 

Peking University Diabetes Center

In December 2003, the Peking University Diabetes Center was proposed for establishment by a number of experts and scholars at the inaugural Peking University Diabetes Symposium and was officially founded in 2004. The center is headed by Professor Qian Rongli as the director, with Professor Ji Linong serving as the executive deputy director, and Professors Guo Xiaohui, Hong Tianpei, and Guan Youfei as deputy directors. Professor C.R. Kahn, the director of the Joslin Diabetes Center at Harvard University in the United States, was invited to serve as the honorary director. With the support of the "985" Phase II project, the center has steadily advanced its organizational construction and the establishment of research platforms. As of 2024, the center has been in existence for 20 years, dedicated to integrating diabetes research resources at Peking University, serving society, and becoming a significant international showcase for China's diabetes research achievements.

The Peking University Diabetes Center leverages the research strengths of Peking University to consolidate diabetes research capabilities, secure research funding and social resources, maintain a leading edge in clinical and basic research, and propel research to international standards. The center focuses on energy metabolism and the pathogenesis of related diseases, conducting studies on the mechanisms of diabetes and its complications, genetics, and islet stem cells. It also undertakes long-term clinical and epidemiological research on large cohort samples of prediabetic and diabetic populations to explore the natural progression of diabetes and its complications in the Chinese population. The center organizes multicenter clinical trials, engages in international and domestic collaborations, and establishes databases for clinical data and biological specimens of diabetic patients. By combining the strengths of three affiliated hospitals and related disciplines, the center conducts research on clinical treatment and systematic management of diabetes. The research findings are promoted nationwide, constructing a diabetes prevention and treatment network centered on the three hospitals with satellite primary care facilities, adapting to changes in the medical market, and driving innovation and development in diabetes prevention and treatment models.

The Peking University Diabetes Center is at the forefront of scientific research in China, focusing on diabetes prevention, the epidemiology of metabolic syndrome, molecular genetics of type 2 diabetes, and personalized diagnosis and treatment. The center has achieved significant results in the prevention, diagnosis, treatment, and application of new technologies for endocrine and metabolic diseases, with its research findings being cited in international guidelines. It has led the development of eight international and national diagnostic and treatment guidelines. The center has published numerous papers in top international journals, and its director, Professor Ji Linong, was consecutively named among Elsevier's "Highly Cited Chinese Researchers" in 2020 and 2021. Professor Ji Linong has conduct more than 80 multicenter clinical trials, including both international and domestic projects, making him the expert with the most new drug and device registration clinical trials in the field of endocrinology and metabolism in China. These trials have provided scientific evidence for improving the treatment of diabetes and metabolic diseases and have contributed evidence-based medical data from the Chinese population to the formulation of prevention and treatment guidelines both domestically and internationally.

Director: Ji Linong

Contact: Ren Qian

Email: qianren@pku.edu.cn

TEL: 0086-10-88324100

Address: N0.11 Xi Zhimen South Street, Xi Cheng District, Beijing, China